Department of Pharmacology

August 16, 2022

Nanoparticles boost anti-cancer immunity

An ingenious targeted nanoparticle approach developed by Vanderbilt researchers reduced tumor burden in a model of ovarian cancer.

By Bill Snyder
February 24, 2022

Melanoma treatment response

Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.

By Sarah E. Glass
February 24, 2022

VUMC researchers find clue to drug-induced arrhythmias

Vanderbilt University Medical Center researchers have made a fundamental discovery about how the heart compensates for genetic variations that otherwise could trigger abnormal and potentially fatal heart rhythms.

By Bill Snyder
November 18, 2021

Seven from VUMC among most highly cited researchers

Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

By Bill Snyder
August 19, 2021

Potential protection from atherosclerosis

Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins.

By Bill Snyder
August 5, 2021

American Heart Association honors Biaggioni’s research

Italo Biaggioni, MD, professor of Medicine and Pharmacology, has been selected as a Distinguished Scientist of the American Heart Association for his contributions to cardiovascular and stroke research.

By Matt Batcheldor
July 8, 2021

Nature’s “recycler” could reduce heart disease risk: study

Researchers at Vanderbilt University Medical Center have identified potential new targets for the prevention of atherosclerosis through the enhancement of autophagy, a natural process for recycling damaged cellular material.
By Bill Snyder
July 1, 2021

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.
By Tom Wilemon
April 8, 2021

Personalized Structural Biology aids cancer treatment decisions

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.
By Bill Snyder
January 21, 2021

NIH grant bolsters research on heart disease, cholesterol

Thanks to major funding from the National Institutes of Health (NIH), researchers at Vanderbilt University Medical Center have made major inroads in understanding how high-density lipoprotein (HDL), commonly known as good cholesterol, in some cases may actually contribute to the development of atherosclerosis.
By Bill Snyder
December 17, 2020

Study reveals new strategy for reducing tumor growth, metastasis

A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.
By Leigh MacMillan
October 22, 2020

Lindsley to direct Center for Neuroscience Drug Discovery

Craig Lindsley, PhD, the William K. Warren Jr. Chair in Medicine and University Professor of Pharmacology, Biochemistry and Chemistry, will become director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery (WCNDD), effective Dec. 1. Lindsley assumes the director position from Jeffrey Conn, PhD, Lee. E. Limbird Chair in Pharmacology and professor of Pharmacology.
By VUMC News and Communications
September 24, 2020

Cohen Fund bolsters Siciliano’s memory research

Cody Siciliano, PhD, assistant professor of Pharmacology in the Vanderbilt University School of Medicine, has been selected to receive a one-year, $100,000 research award from the Stanley Cohen Innovation Fund to support his studies of the neural substrates of memory.
By Bill Snyder
1 2 3 4 … 14